Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 5/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | F11 | P03951 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4421090 | 0.74 | MAPKAPK2 (0.44) | MAPKAPK2RPS6KA3CSNK2A1PLK3 | |
| SCHEMBL5738855 | 0.72 | MAPK1 (0.50) | MAPK1CA12CA9F11CA1 | |
| SCHEMBL5828085 | 0.70 | CHEK1 (0.42) | MAPK1MEN1KMT2AEGFRCSNK2A1 | |
| SCHEMBL4422632 | 0.70 | KMO (0.44) | PDE3BPDE3APOLB | |
| SCHEMBL4427818 | 0.70 | CMA1 (0.38) | PDE3BPDE3A | |
| SCHEMBL17511896 | 0.70 | PI4KA (0.43) | KMT2APIK3CDEGFRPIK3CA | |
| SCHEMBL17951770 | 0.68 | MAPK1 (0.68) | MAPK1CA12CA9F11CA1 | |
| SCHEMBL10423740 | 0.68 | MAPK1 (0.50) | MAPK1CA12CA9F11CA1 | |
| SCHEMBL4427247 | 0.68 | MAPK1 (0.46) | MAPK1CA12CA9F11CA1 | |
| SCHEMBL4420255 | 0.68 | LMNA (0.45) | PDE3BPDE3AMEN1KMT2ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0635507-B1 | Tricyclic derivatives and their use as anti-cancer agents | ZENECA LTD (GB) | 1999-09-15 | — | — | EP | claimed |
| US-5569658-A | Tricyclic derivatives | ZENECA LIMITED (GB) | 1996-10-29 | — | — | US | claimed |
| EP-0635507-A1 | Tricyclic derivatives and their use as anti-cancer agents | ZENECA LIMITED (GB) | 1995-01-25 | — | — | EP | claimed |
| US-7498335-B2 | Method of producing an antiangiogenic or vascular permeability reducing effect | ASTRAZENECA AB (CH) | 2009-03-03 | — | — | US | disclosed |
| US-7001904-B1 | Guanidine derivatives quinazoline and quinoline for use in the treatment of autoimmune diseases | ASTRAZENECA AB (SE) | 2006-02-21 | — | — | US | disclosed |
| EP-1272185-B1 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| US-6806274-B1 | IMMUNOREGULATION OR IMMUNOSUPPRESSIVE AGENTS; TYROSINE KINASE INHIBITORS; PREVENTING ORGAN TRANSPLANT REJECTION; AUTOIMMUNE CONDITIONS; REDUCED SIDE EFFECTS | ASTRAZENECA UK LIMITED (GB) | 2004-10-19 | — | — | US | disclosed |
| US-20030225111-A1 | Therapy | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | disclosed |
| EP-1296973-A1 | GUANIDINE DERIVATIVES OF QUINAZOLINE AND QUINOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | AstraZeneca AB (SE) | 2003-04-02 | — | — | EP | disclosed |
| WO-2002000644-A1 | GUANIDINE DERIVATIVES OF QUINAZOLINE AND QUINOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | ASTRAZENECA AB (SE) | 2002-01-03 | — | — | WO | disclosed |
| EP-0635507-B1 | Tricyclic derivatives and their use as anti-cancer agents | ZENECA LTD (GB) | 1999-09-15 | — | — | EP | disclosed |
| US-5569658-A | Tricyclic derivatives | ZENECA LIMITED (GB) | 1996-10-29 | — | — | US | disclosed |
| EP-0635507-A1 | Tricyclic derivatives and their use as anti-cancer agents | ZENECA LIMITED (GB) | 1995-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225111-A1 | Therapy | VEGFA, AQP1, FLT1 | MAPK1 813/4885CA12 1090/4885CA9 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.